Publications
Advancing knowledge in chronic liver disease through evidence-based research.
AbstractsPublication policy

Showing 10 of 147 papers

Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure

Mookerjee RP, Pavesi M, Thomsen KL, Mehta G, Macnaughtan J, Bendtsen F, Coenraad M, Sperl J, Gines P, Moreau R, Arroyo V, Jalan R; CANONIC Study Investigators of the EASL-CLIF Consortium

J Hepatol 2016, 64(3): 574–582

DOI: 10.1016/j.jhep.2015.10.018

Neuroinflammation in liver disease: sessional talks from ISHEN

Wright G, Swain M, Annane D, Saliba F, Samuel D, Arroyo V, DeMorrow S, Witt A.

Metab Brain Dis 2016, 31(6): 1339–1354

DOI: 10.1007/s11011-016-9918-7

Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure

Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, Alessandria C, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel TM, Albillos A, Gustot T, Benten D, Durand F, Ginès P, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF).

Hepatology 2016, 64(4): 1249–1264

DOI: 10.1002/hep.28740

Clinical course and short-term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis

Fernández J, Acevedo J, Prado V, Mercado M, Castro M, Pavesi M, Arteaga M, Sastre L, Juanola A, Ginès P, Arroyo V.

Liver Int 2017, 37(3): 385–395

DOI: 10.1111/liv.13239

Prognostic value of C-reactive protein in cirrhosis: External validation from the CANONIC cohort

Cervoni JP, Amorós À, Bañares R, Luis Montero J, Soriano G, Weil D, Moreau R, Pavesi M, Thévenot T, Di Martino V; EASL-CLIF Consortium

Eur J Gastroenterol Hepatol 2016, 28(9): 1028–1034

DOI: 10.1097/MEG.0000000000000676

Signaling and immunoresolving actions of resolvin D1 in inflamed human visceral adipose tissue

Titos E, Rius B, López-Vicario C, Alcaraz-Quiles J, García-Alonso V, Lopategi A, Dalli J, Lozano JJ, Arroyo V, Delgado S, Serhan CN, Clària J.

J Immunol 2016, 197(8): 3360–3370

DOI: 10.4049/jimmunol.1502522

Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis

Ariza X, Graupera I, Coll M, Solà E, Barreto R, García E, Moreira R, Elia C, Morales-Ruiz M, Llopis M, Huelin P, Solé C, Fabrellas N, Weiss E, Nevens F, Gerbes A, Trebicka J, Saliba F, Fondevila C, Hernández-Gea V, Fernández J, Bernardi M, Arroyo V, Jiménez W, Deulofeu C, Pavesi M, Angeli P, Jalan R, Moreau R, Sancho-Bru P, Ginès P; CANONIC Investigators, EASL CLIF Consortium.

J Hepatol 2016, 65(1): 57–65

DOI: 10.1016/j.jhep.2016.03.002

Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis

Solà E, Kerbert AJ, Verspaget HW, Moreira R, Pose E, Ruiz P, Cela R, Morales-Ruiz M, López E, Graupera I, Solé C, Huelin P, Navarro AA, Ariza X, Jalan R, Fabrellas N, Benten D, de Prada G, Durand F, Jimenez W, van der Reijden JJ, Fernandez J, van Hoek B, Coenraad MJ, Ginès P.

J Hepatol 2016, 65(5): 914–920

DOI: 10.1016/j.jhep.2016.07.003

Characteristics, diagnosis and prognosis of acute-on-chronic liver failure in cirrhosis associated to hepatitis B

Li H, Chen LY, Zhang NN, Li ST, Zeng B, Pavesi M, Amorós À, Mookerjee RP, Xia Q, Xue F, Ma X, Hua J, Sheng L, Qiu DK, Xie Q, Foster GR, Dusheiko G, Moreau R, Gines P, Arroyo V, Jalan R.

Sci Rep 2016, 6: 25487

DOI: 10.1038/srep25487

Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)

Grønbæk H, Rødgaard-Hansen S, Aagaard NK, Arroyo V, Moestrup SK, Garcia E, Solà E, Domenicali M, Piano S, Vilstrup H, Møller HJ; CANONIC study investigators of the EASL-CLIF Consortium.

J Hepatol 2016, 64(4): 813–822

DOI: 10.1016/j.jhep.2015.11.021